A5057981035- Inflammatory Bowel Disease
- Microscopic Colitis
- Biosimilars and Bioanalytical Methods
- Liver Diseases and Immunity
- Eosinophilic Esophagitis
- Immunodeficiency and Autoimmune Disorders
- Autoimmune and Inflammatory Disorders
- Celiac Disease Research and Management
- Gastrointestinal motility and disorders
- Diagnosis and treatment of tuberculosis
- Helicobacter pylori-related gastroenterology studies
- Tuberculosis Research and Epidemiology
- Systemic Lupus Erythematosus Research
- SARS-CoV-2 and COVID-19 Research
- Hepatitis B Virus Studies
- Chronic Lymphocytic Leukemia Research
- Health Systems, Economic Evaluations, Quality of Life
- Pharmaceutical studies and practices
- IL-33, ST2, and ILC Pathways
- Psoriasis: Treatment and Pathogenesis
- Hepatitis C virus research
- Hidradenitis Suppurativa and Treatments
- Autoimmune and Inflammatory Disorders Research
- Diverticular Disease and Complications
- Immune Cell Function and Interaction
Azienda Ospedaliera G. Brotzu
2016-2025
Gastroenterology Hospital "Saverio de Bellis"
2024
University of Padua
2023
Società Italiana di Reumatologia
2019
Sapienza University of Rome
2014
Catholic University of America
2012-2013
Università Cattolica del Sacro Cuore
2008-2012
Hospital Universitario de La Princesa
2007
The use of ustekinumab and vedolizumab as second-line therapies in patients with Crohn's disease (CD) which tumour necrosis factor alpha inhibitors (TNFi) failed is still debated. aim this study was to compare, a large multicenter observational retrospective cohort, the effectiveness therapies, assessed by clinical objective outcomes including endoscopy gastrointestinal imaging.Clinical response, remission, steroid-free remission at weeks 26 52 were evaluated propensity score-weighted...
Journal Article Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: Effects of combined therapy immunosuppressants Get access G. Andrisani, Andrisani aOperative Unit Internal Medicine and Gastroenterology, Complesso integrato Columbus, Catholic University Sacro Cuore, Roma, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar D. Frasca, Frasca bDepartment Microbiology Immunology, Miller School...
Background Ustekinumab (UST) is an interleukin-12/interleukin-23 receptor antagonist recently approved for treating ulcerative colitis (UC) but with limited real-world data. Therefore, we evaluated the effectiveness and safety of UST in patients UC a setting.
Background: The prevalence rates of hepatitis B virus (HBV) and C (HCV) in patients with inflammatory bowel disease (IBD) have been reported to be higher than infection among the general population. Although several cases HBV reactivation IBD treated anti-TNF-α agents described, no evidence exists that therapy exacerbates course HCV. aims this study were assess HCV rate vaccination a population patients; investigate long-term effects subgroup or infections.
Abstract Background Short bowel syndrome (SBS) is a malabsorptive condition mostly caused by massive surgical resection of the small intestine and associated with significant morbidity mortality, reduced quality life, high healthcare costs1. Crohn’s disease (CD) represents potential cause leading to an increased risk SBS considerable clinical consequences2. Human microbiota-associated (HMA) mice represent model establish human fecal microbiota in preclinical models3-4. Here, for first time,...
Abstract Background Short bowel syndrome(SBS)is a severe clinical condition occuring when,following multiple intestinal resections,the remaining small in continuity is ≤200cm.SBS associated with failure(IF)when the absorptive function compromised,requiring intravenous nutritional or electrolyte supplementation.Crohn’s disease(CD)is one of adults’ most frequent causes SBS.The aim this study was to identify predictive factors SBS CD pts Methods We performed prospective study, enrolling...
Abstract Background Computational drug discovery is a powerful, cost-effective approach for accelerating development, providing key insights into modulating the GLP-2 receptor (GLP-2R), an important target gastrointestinal diseases like short bowel syndrome1. Methods This study uses diverse in silico molecular design methods, mainly virtual screening2-3, to discover nonpeptidic small-molecule GLP-2R agonists that overcome drawbacks of peptide-based treatments. The first strategy identifies...
Abstract Background The best maintenance therapy after a steroid-responsive acute severe ulcerative colitis (ASUC) episode remains poorly studied and is not addressed in current guidelines. We aimed to compare the impact of different treatment strategies following hospitalization for ASUC. Methods Multicentric, multinational, retrospective cohort study including patients hospitalized with ASUC, between 2010-2021, who responded intravenous steroids (Oxford Criteria). Patients were categorized...
Abstract Background Adalimumab (ADA) and vedolizumab (VDZ) have shown efficacy in moderate to severe ulcerative colitis (UC) patients who failed infliximab (IFX). Although, a comparative evaluation of ADA VDZ this clinical setting is currently missing. Aim The aim study compare the affected by UC IFX. Methods Clinical records from 8 Italian IBD referral centers IFX were candidates receive either or retrospectively reviewed. primary end point was therapeutic failure at week 52. Secondary...
Abstract Background Adalimumab (ADA) biosimilars have entered the therapeutic armamentarium of inflammatory bowel disease (IBD), allowing for treatment a greater number patients their reduced cost than originator. However, comparative data on efficacy and safety various ADA remains scarce. We compare SB5, ABP501, GP2017, MSB11022 in treating IBD outpatients real-life Italian setting. Methods A retrospective analysis was performed consecutive with complete clinical, laboratory, endoscopic...
Infliximab and adalimumab are widely used for the treatment of Crohn's disease ulcerative colitis.To compare long-term efficacy safety infliximab in a large cohort colitis patients reflecting real-life clinical practice.Seven hundred twelve were retrospectively reviewed, 410 with (268 treated 142 infliximab; median follow-up 60 months, range, 36-72) 302 (118 184 48 36-84).In disease, remission was maintained 75.0% vs. 72.5% (P = 0.699); mucosal healing steroid-free 49.5% 63.9% 0.077) 77.7%...
The therapeutic armamentarium for managing Crohn's disease (CD) has expanded significantly in recent decades. Several biologics with three different mechanisms of action [anti-tumor necrosis factor (TNF)-α, anti-integrin α4β7, and anti-IL 12/23] are currently available to manage CD.
Inflammatory bowel diseases, comprising Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, relapsing, remitting immune-mediated inflammatory diseases affecting the gastrointestinal tract. Ustekinumab (UST) is a monoclonal antibody that blocks p40 subunit of anti-interleukin (IL) 12/23. Pivotal trials (CERTIFI UNITI-IM for CD, UNIFI UC) established efficacy UST induction maintenance remission in both CD UC, with most favorable results naïve patients to biologics. In recent years,...
Mild-to-moderate ulcerative colitis (UC) management is centred on 5-aminosalicylic acid (5-ASA) derivatives. Whether supplementing 5-ASA with nutraceuticals can provide real advantages in UC-relevant outcomes unclear. This retrospective multicentre study compared clinical remission, response rates, and faecal calprotectin levels a two-arm design, including patients treated alone those additional H. erinaceus-based multi-compound supplementation. In the group, rates were 41% at three months...